Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Prevail Therapeutics

Nasdaq:PRVL
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PRVL
Nasdaq
$400M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The last earnings update was 2 days ago. More info.


Add to Portfolio Compare Print
  • Prevail Therapeutics has significant price volatility in the past 3 months.
PRVL Share Price and Events
7 Day Returns
-4.7%
NasdaqGM:PRVL
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-
NasdaqGM:PRVL
0%
US Biotechs
-11.5%
US Market
PRVL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Prevail Therapeutics (PRVL) -4.7% -21.8% -25.9% - - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • No trading data on PRVL.
  • No trading data on PRVL.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

PRVL Value

 Is Prevail Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Prevail Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $11.72.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Prevail Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Prevail Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:PRVL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.22
NasdaqGM:PRVL Share Price ** NasdaqGM (2020-03-27) in USD $11.72
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Prevail Therapeutics.

NasdaqGM:PRVL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:PRVL Share Price ÷ EPS (both in USD)

= 11.72 ÷ -2.22

-5.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prevail Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Prevail Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Prevail Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:PRVL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-13.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Prevail Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Prevail Therapeutics's assets?
Raw Data
NasdaqGM:PRVL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $4.84
NasdaqGM:PRVL Share Price * NasdaqGM (2020-03-27) in USD $11.72
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:PRVL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:PRVL Share Price ÷ Book Value per Share (both in USD)

= 11.72 ÷ 4.84

2.42x

* Primary Listing of Prevail Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prevail Therapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Prevail Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Prevail Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PRVL Future Performance

 How is Prevail Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-13.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Prevail Therapeutics expected to grow at an attractive rate?
  • Unable to compare Prevail Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Prevail Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Prevail Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:PRVL Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:PRVL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -13.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:PRVL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:PRVL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 23 -138 -131 3
2023-12-31 5 -134 -114 3
2022-12-31 1 -120 -103 4
2021-12-31 0 -114 -92 3
2020-12-31 0 -103 -81 3
2020-03-28
NasdaqGM:PRVL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -56 -63
2019-09-30 -47 -52
2019-06-30 -32 -37
2019-03-31 -25 -26
2018-12-31 -14 -19
2017-12-31 -2 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Prevail Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Prevail Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:PRVL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Prevail Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PRVL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -2.62 -1.44 -3.82 3.00
2023-12-31 -2.40 -1.68 -3.06 3.00
2022-12-31 -2.27 -1.89 -2.80 3.00
2021-12-31 -2.23 -1.98 -2.55 3.00
2020-12-31 -2.25 -2.18 -2.38 3.00
2020-03-28
NasdaqGM:PRVL Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.22
2019-09-30 -2.65
2019-06-30 -5.55
2019-03-31 -7.80
2018-12-31 -6.01
2017-12-31 -1.46

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Prevail Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Prevail Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Prevail Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PRVL Past Performance

  How has Prevail Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Prevail Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Prevail Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Prevail Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Prevail Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Prevail Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Prevail Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PRVL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -63.19 17.01 48.80
2019-09-30 -52.10 12.21 42.22
2019-06-30 -36.99 8.68 29.98
2019-03-31 -25.83 5.93 21.23
2018-12-31 -19.09 4.68 14.13
2017-12-31 -3.65 1.61 1.99

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Prevail Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Prevail Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Prevail Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Prevail Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Prevail Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PRVL Health

 How is Prevail Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Prevail Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Prevail Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Prevail Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Prevail Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 9.8212811823833E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Prevail Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:PRVL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 165.34 0.00 168.05
2019-09-30 182.03 0.00 183.07
2019-06-30 201.04 0.00 202.10
2019-03-31 101.79 0.00 100.27
2018-12-31 61.29 0.00 63.01
2017-12-31 2.58 7.77 12.74
  • Prevail Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Prevail Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Prevail Therapeutics has sufficient cash runway for 2.9 years based on current free cash flow.
  • Prevail Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 91.6% each year.
X
Financial health checks
We assess Prevail Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Prevail Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PRVL Dividends

 What is Prevail Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Prevail Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Prevail Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Prevail Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Prevail Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:PRVL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:PRVL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Prevail Therapeutics has not reported any payouts.
  • Unable to verify if Prevail Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Prevail Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Prevail Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Prevail Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Prevail Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Prevail Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Prevail Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PRVL Management

 What is the CEO of Prevail Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Asa Abeliovich
COMPENSATION $4,085,762
AGE 54
TENURE AS CEO 2.7 years
CEO Bio

Dr. Asa Abeliovich, M.D., Ph.D., is the Founder of Prevail Therapeutics Inc. He serves as Chief Executive Officer and Director of Prevail Therapeutics Inc., since July 2017 and also serves as its President. Dr. Abeliovich has extensive industry expertise in scientific, business and executive management experience in the biotechnology industry. Prior to founding Prevail Therapeutics Inc., he was a co-Founder of Alector, Inc. and served as the Consulting Chief Innovation Officer from October 2013 to July 2017. Previously, he served as a tenured Associate Professor of Pathology, Cell Biology and Neurology at Columbia University and as a Member of the Taub Institute for Alzheimer’s Disease and the Aging Brain. He also served as an attending physician at Neurology at the New York-Presbyterian Hospital and the New York Psychiatric Institute. He is currently on the Scientific Advisory Board of the Silverstein Foundation for Parkinson’s with GBA. Dr. Abeliovich received an M.D. from Harvard Medical School, a Ph.D. from Massachusetts Institute of Technology, and bachelor degrees in Life Sciences and Humanities from the Massachusetts Institute of Technology.

CEO Compensation
  • Insufficient data for Asa to compare compensation growth.
  • Asa's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Prevail Therapeutics management team in years:

2
Average Tenure
49
Average Age
  • The tenure for the Prevail Therapeutics management team is about average.
Management Team

Asa Abeliovich

TITLE
Founder
COMPENSATION
$4M
AGE
54
TENURE
2.7 yrs

Franz Hefti

TITLE
Chief Development Officer
COMPENSATION
$1M
AGE
70
TENURE
2 yrs

Jeff Sevigny

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
50
TENURE
2 yrs

Brett Kaplan

TITLE
Chief Financial Officer
AGE
45
TENURE
1.3 yrs

Yong Dai

TITLE
Chief Technology Officer
AGE
48
TENURE
1.1 yrs

Emily Minkow

TITLE
Chief Business Officer
AGE
37
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Prevail Therapeutics board of directors in years:

2.3
Average Tenure
59
Average Age
  • The average tenure for the Prevail Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Francois Nader

TITLE
Non-Executive Chairman
COMPENSATION
$288K
AGE
62

Asa Abeliovich

TITLE
Founder
COMPENSATION
$4M
AGE
54
TENURE
2.7 yrs

Tim Adams

TITLE
Independent Director
AGE
59
TENURE
0.9 yrs

Carl Gordon

TITLE
Director
AGE
54
TENURE
2.6 yrs

Ran Nussbaum

TITLE
Independent Director
AGE
46
TENURE
2 yrs

Peter Thompson

TITLE
Independent Director
AGE
59
TENURE
2.6 yrs

Morgan Sheng

TITLE
Independent Director
AGE
61
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
26. Jun 19 Buy OrbiMed Advisors LLC Company 24. Jun 19 24. Jun 19 882,352 $17.00 $14,999,984
X
Management checks
We assess Prevail Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Prevail Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PRVL News

Simply Wall St News

PRVL Company Info

Description

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company’s lead product candidate is PR001 for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. has a strategic collaboration with Lonza Group Ltd to develop and manufacture PR001 and PR006; and a license agreement with REGENXBIO Inc. for GBA1. The company was founded in 2017 and is headquartered in New York, New York.

Details
Name: Prevail Therapeutics Inc.
PRVL
Exchange: NasdaqGM
Founded: 2017
$400,482,725
34,170,881
Website: http://www.prevailtherapeutics.com
Address: Prevail Therapeutics Inc.
430 East 29th Street,
Suite 940,
New York,
New York, 10016,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM PRVL Common Stock Nasdaq Global Market US USD 20. Jun 2019
Number of employees
Current staff
Staff numbers
55
Prevail Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 04:55
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.